Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | TBCRC 048: olaparib monotherapy in metastatic breast cancer

Nadine Tung, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA, talks about the phase II study of olaparib monotherapy in patients with metastatic breast cancer with germline or somatic mutations in DNA damage response (DDR) pathway genes. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).